Prognostic Significance of CDK1 Expression in Diffuse Large B-Cell Lymphoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2025 Jan 8

PMID 39773464

Authors

Qiuni Chen

Lei Xu

Chuanyang Lu

Yujie Xue

Xue Gong

Yuye Shi

Chunling Wang

Liang Yu

Affiliations

Soon will be listed here.

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adult, characterized by uncontrolled cell proliferation and strong aggressiveness. Previous studies have found that cyclin-dependent kinase 1(CDK1) are related to tumor growth and metastasis. However, the role of CDK1 in DLBCL is exclusive. This study investigated the clinical implications and expression of CDK1 in DLBCL.

Methods: Gene expression data for healthy subjects were sourced from the Genotype-Tissue Expression repository. Clinical details and survival statistics of patients with DLBCL were obtained from the Gene Expression Omnibus archive (GSE10846). Patients were categorized based on CDK1 expression levels, and differences in clinical outcomes between the groups were examined. Univariate and multivariate Cox regression analyses were used to ascertain whether CDK1 expression independently predicted DLBCL prognosis. The protein expression of CDK1 was gauged by immunohistochemistry. Additionally, we investigated the effect of CDK1 inhibition on DLBCL cell growth and death using the Cell Counting Kit-8 and flow cytometry.

Results: In the control group, CDK1 expression was predominantly observed in the hematopoietic and reproductive systems. CDK1 levels in patients with DLBCL were notably elevated compared with those in controls. Significant differences were noted in the lactate dehydrogenase ratio and overall survival based on CDK1 expression. Statistical analyses confirmed that CDK1 was an independent predictor of DLBCL outcomes. Elevated CDK1 protein levels were observed in a significant number of DLBCL samples, in contrast to normal lymph node samples from individuals without lymphoma. The inhibitor Ro-3306 curtails DLBCL cell growth and enhances cell death in vitro.

Conclusions: Elevated CDK1 levels are correlated with poor prognosis in patients with DLBCL.

References

Zhao H, Li S, Wang G, Zhao W, Zhang D, Wang F . Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1-involved pathway. Cancer Med. 2019; 8(9):4348-4358. PMC: 6675732. DOI: 10.1002/cam4.2324. View

Zhou Z, Sehn L, Rademaker A, Gordon L, LaCasce A, Crosby-Thompson A . An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2013; 123(6):837-42. PMC: 5527396. DOI: 10.1182/blood-2013-09-524108. View

Alduaij W, Collinge B, Ben-Neriah S, Jiang A, Hilton L, Boyle M . Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population. Blood. 2022; 141(20):2493-2507. DOI: 10.1182/blood.2022018248. View

Asghar U, Witkiewicz A, Turner N, Knudsen E . The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015; 14(2):130-46. PMC: 4480421. DOI: 10.1038/nrd4504. View

Radomska H, Alberich-Jorda M, Will B, Gonzalez D, Delwel R, Tenen D . Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα. J Clin Invest. 2012; 122(8):2955-66. PMC: 3408728. DOI: 10.1172/JCI43354. View

Huang Z, Shen G, Gao J . CDK1 promotes the stemness of lung cancer cells through interacting with Sox2. Clin Transl Oncol. 2021; 23(9):1743-1751. DOI: 10.1007/s12094-021-02575-z. View

Hedblom A, Laursen K, Miftakhova R, Sarwar M, Anagnostaki L, Bredberg A . CDK1 interacts with RARγ and plays an important role in treatment response of acute myeloid leukemia. Cell Cycle. 2013; 12(8):1251-66. PMC: 3674090. DOI: 10.4161/cc.24313. View

. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013; 45(6):580-5. PMC: 4010069. DOI: 10.1038/ng.2653. View

Li J, Wang Y, Wang X, Yang Q . CDK1 and CDC20 overexpression in patients with colorectal cancer are associated with poor prognosis: evidence from integrated bioinformatics analysis. World J Surg Oncol. 2020; 18(1):50. PMC: 7055103. DOI: 10.1186/s12957-020-01817-8. View

10.

Zou Y, Ruan S, Jin L, Chen Z, Han H, Zhang Y . CDK1, CCNB1, and CCNB2 are Prognostic Biomarkers and Correlated with Immune Infiltration in Hepatocellular Carcinoma. Med Sci Monit. 2020; 26:e925289. PMC: 7482506. DOI: 10.12659/MSM.925289. View

11.

Yasukawa M, Ando Y, Yamashita T, Matsuda Y, Shoji S, Morioka M . CDK1 dependent phosphorylation of hTERT contributes to cancer progression. Nat Commun. 2020; 11(1):1557. PMC: 7096428. DOI: 10.1038/s41467-020-15289-7. View

12.

Zheng H, Huang Z, He R, Lu H, Dang Y, Lin P . Integrated assessment of CDK1 upregulation in thyroid cancer. Am J Transl Res. 2020; 11(12):7233-7254. PMC: 6943461. View

13.

Lu X, Pang Y, Cao H, Liu X, Tu L, Shen Y . Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors. Cancer Res. 2021; 81(9):2481-2494. DOI: 10.1158/0008-5472.CAN-20-3580. View

14.

Wolowiec D, Berger F, Ffrench P, Bryon P, Ffrench M . CDK1 and cyclin A expression is linked to cell proliferation and associated with prognosis in non-Hodgkin's lymphomas. Leuk Lymphoma. 1999; 35(1-2):147-57. DOI: 10.3109/10428199909145714. View

15.

Nagato T, Ueda S, Takahara M, Kishibe K, Komabayashi Y, Kumai T . Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma. Lab Invest. 2019; 99(5):612-624. DOI: 10.1038/s41374-018-0182-9. View

16.

Tukiainen T, Villani A, Yen A, Rivas M, Marshall J, Satija R . Landscape of X chromosome inactivation across human tissues. Nature. 2017; 550(7675):244-248. PMC: 5685192. DOI: 10.1038/nature24265. View

17.

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

18.

He M, Kridel R . Treatment resistance in diffuse large B-cell lymphoma. Leukemia. 2021; 35(8):2151-2165. DOI: 10.1038/s41375-021-01285-3. View

19.

Zhao X, Gartenhaus R . Phospho-p70S6K and cdc2/cdk1 as therapeutic targets for diffuse large B-cell lymphoma. Expert Opin Ther Targets. 2009; 13(9):1085-93. DOI: 10.1517/14728220903103833. View

20.

Lossos I . Diffuse large B cell lymphoma: from gene expression profiling to prediction of outcome. Biol Blood Marrow Transplant. 2008; 14(1 Suppl 1):108-11. PMC: 2729179. DOI: 10.1016/j.bbmt.2007.10.020. View